TABLE 1.
Patient characteristics with ICI‐associated transplant rejection (n = 168)
| n | % | |
|---|---|---|
| Reporting region | ||
| America | 80 | 47.6% |
| Europe | 71 | 42.3% |
| Asia | 0 | |
| Oceania | 7 | 4.2% |
| Africa | 1 | 0.6% |
| Missing | 9 | 5.4% |
| Reporter type | ||
| Healthcare professional | 144 | 85.7% |
| Non‐healthcare | 23 | 13.7% |
| Missing | 1 | 0.6% |
| Reporting year | ||
| 2021 Q1–Q2 | 18 | 10.7% |
| 2020 | 36 | 21.4% |
| 2019 | 43 | 25.6% |
| 2018 | 35 | 20.8% |
| 2017 | 27 | 16.1% |
| 2016 | 9 | 5.4% |
| Gender | ||
| Male | 96 | 57.1% |
| Female | 29 | 17.3% |
| Missing | 43 | 25.6% |
| Age | ||
| Median | 64 (14–85) | |
| <18 | 4 | 2.4% |
| 18–44 | 10 | 6.0% |
| 45–64 | 50 | 29.8% |
| 65–74 | 50 | 29.8% |
| ≥75 | 8 | 4.8% |
| Missing | 46 | 27.4% |
| Anti‐PD‐1 | 144 | 85.7% |
| Nivolumab | 96 | 57.1% |
| Pembrolizumab | 41 | 24.4% |
| Cemiplimab | 7 | 4.2% |
| Anti‐PD‐L1 | 34.0% | |
| Avelumab | 1 | 0.6% |
| Anti‐CTLA4 | ||
| Ipilimumab | 6 | 3.6% |
| Combination therapy | 17 | 10.1% |
| Nivolumab + Ipilimumab | 8 | 4.8% |
| Pembrolizumab + Ipilimumab | 7 | 4.2% |
| Pembrolizumab + Nivolumab | 2 | 1.2% |
| Indications for ICI | ||
| Malignant melanoma | 73 | 43.5% |
| Lung cancer | 28 | 16.7% |
| Hepatic cancer | 23 | 13.7% |
| Skin cancer | 15 | 8.9% |
| Renal cell carcinoma | 5 | 3.0% |
| Metastatic carcinoma | 3 | 1.8% |
| Other carcinoma | 9 | 5.4% |
| Unspecified | 12 | 7.1% |
| Type of transplant rejection | ||
| Kidney | 104 | 61.9% |
| Liver | 28 | 16.7% |
| Heart | 6 | 3.6% |
| Lung | 1 | 0.6% |
| Unspecified | 29 | 17.3% |
| Time to rejection onset, Median days (min–max) | 23 (1–169) | |
| Kidney | 15 (1–85) | |
| Liver | 23 (7–169) | |
| Outcome | ||
| Hospitalization | 25 | 14.9% |
| Disability | 5 | 3.0% |
| Life‐threatening | 5 | 3.0% |
| Death | 54 | 32.1% |